|
|
Latest Bladder Cancer News
Components of Processed Meat May Increase Risk of Bladder Cancer (8/10/2010)
People who consume a large amount of nitrite and nitrate from processed meat may be at an increased risk for developing bladder cancer, according to a study published in Cancer.
Study Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Painters May Have Higher Risk of Bladder Cancer (7/29/2010)
Occupational exposures appear to increase bladder cancer risk in painters, according to a study published in Occupational and Environmental Medicine.
Exposure to Aromatic Amines Poses Long-term Risk of Bladder Cancer (6/25/2010)
Workers exposed to aromatic amines continued to experience an increased risk of bladder cancer even 30 years after exposure, according to the results of a follow-up study published in the Journal of the National Cancer Institute.
Sequential Chemotherapy Benefits Node-positive Breast Cancer Patients (6/18/2010)
Women with operable node-positive breast cancer experienced a survival benefit from sequential administration of doxorubicin, cyclophosphamide, and Taxotere® (docetaxel).
Bladder Cancer News By Topic
Bladder Cancer - Screening/PreventionComponents of Processed Meat May Increase Risk of Bladder Cancer (8/10/2010)
People who consume a large amount of nitrite and nitrate from processed meat may be at an increased risk for developing bladder cancer, according to a study published in Cancer.
Painters May Have Higher Risk of Bladder Cancer (7/29/2010)
Occupational exposures appear to increase bladder cancer risk in painters, according to a study published in Occupational and Environmental Medicine.
Exposure to Aromatic Amines Poses Long-term Risk of Bladder Cancer (6/25/2010)
Workers exposed to aromatic amines continued to experience an increased risk of bladder cancer even 30 years after exposure, according to the results of a follow-up study published in the Journal of the National Cancer Institute.
Vitamins C, D, and E Don’t Reduce Risk of Bladder Cancer (6/7/2010)
Long-term use of vitamin C, vitamin D, or vitamin E does not appear to reduce the risk of bladder cancer. These results were presented at the 2010 annual meeting of the American Urological Association.
Study Evaluates Long-term Effects of Arsenic in Drinking Water on Bladder Cancer (6/4/2010)
Death rate from bladder cancer continues to rise 20 years after exposure to high levels of arsenic in drinking water. These findings were recently presented at the 105th Annual Scientific Meeting of the American Urological Association (AUA).
Bladder Cancer - Stages 0-IAge Influences Response to Bladder Cancer Immunotherapy (6/19/2006)
Among patients with superficial bladder cancer, response to intravesical immunotherapy (immunotherapy drugs administered directly into the bladder) appears to decline with age. These results were published in The Journal of Urology.
Repeated Surgery May Benefit Patients with Stage I Bladder Cancer (5/23/2006)
Among patients with stage I bladder cancer, repeated transurethral resection may improve patient outcomes. These results were published in The Journal of Urology.
High-Volume Hospitals Offer Better Outcomes After Radical Cystectomy and Radical Prostatectomy (5/8/2006)
Among patients undergoing radical cystectomy (removal of bladder) or radical prostatectomy (removal of prostate), the probability of dying during hospitalization was lower at hospitals that performed a greater number of these specific procedures (high-volume hospitals). Hospital volume was not linked with in-hospital mortality after radical nephrectomy (removal of kidney). These results were published in the Journal of Clinical Oncology.
Addition of NMP22® BladderChek® Improves Detection of Recurrent Bladder Cancer (1/18/2006)
According to a recent article published in the Journal of the American Medical Association, the addition of the NMP22® BladderChek® test to cystoscopy improves the detection of recurrent bladder cancer compared to cystoscopy alone.
BCG/Mitomycin C Improves Outcomes Compared to BCG Alone in Stage I Bladder Cancer (1/3/2006)
According to a recent article published in Lancet Oncology, the combination of BCG plus electromotive mitomycin C improves outcomes compared to BCG alone in the treatment of superficial bladder cancer.
Bladder Cancer - Stages II-IIIStudy Evaluates Incidence of Lymphedema Resulting from Cancer Treatment (8/9/2010)
A systematic review of 47 studies evaluating treatment for melanoma, head and neck cancer, genitourinary cancers, gynecologic cancers, and sarcoma indicates that lymphedema is a common side effect of treatment for these diseases.
Sequential Chemotherapy Benefits Node-positive Breast Cancer Patients (6/18/2010)
Women with operable node-positive breast cancer experienced a survival benefit from sequential administration of doxorubicin, cyclophosphamide, and Taxotere® (docetaxel).
Radical Cystectomy Improves Survival in Stage II Bladder Cancer (5/4/2010)
Radical cystectomy can improve outcomes among patients with muscle-invasive bladder cancer but appears to be underused in this patient population. These results were published in the Journal of the National Cancer Insitute.
Combined Modality Therapy Preserves Bladder and Offers Long-term Survival in Invasive Bladder Cancer (3/18/2010)
Combined modality therapy (CMT) preserves the bladder, achieves complete response (CR), and offers long-term survival in approximately 70% of patients with invasive bladder cancer, according to the results of a 15-year study presented at 2010 American Society of Clinical Oncology Genitourinary Symposium March 5-7 in San Francisco.
Delaying Surgery Shortens Survival in Stage II Bladder Cancer (3/13/2009)
Among patients with Stage II bladder cancer, those who undergo surgery more than 12 weeks after diagnosis have a higher risk of death. These results were published in the journal Cancer.
Bladder Cancer - Stage IV/MetastaticGemzar® and Taxol® Effective First-line Therapy for Previously Untreated Bladder Cancer (5/27/2009)
The combination of Gemzar® (gemcitabine) and Taxol® (paclitaxel) is an effective first-line treatment for bladder cancer, according to an early online publication of Cancer.
Update on the Management of Genitourinary Malignancies (10/12/2007)
A Report from the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Herceptin® Evaluated in Advanced Bladder Cancer (7/16/2007)
According to the results of a Phase II clinical trial, Herceptin® (trastuzumab)—a targeted therapy used in the treatment of HER2-positive breast cancer—may have a role in the treatment of HER2-positive advanced bladder cancer. Larger studies will be necessary to further evaluate Herceptin in bladder cancer.
Gemzar® and Eloxatin® Promising for Advanced Bladder Cancer (8/21/2006)
According to an article recently published in the Annals of Oncology, the chemotherapy combination consisting of Eloxatin® (oxaliplatin) and Gemzar® (gemcitabine) is an effective and well-tolerated regimen for advanced bladder cancer. Patients who are not able to tolerate chemotherapy regimens including Platinol® (ciplatin) may be considered candidates for Eloxatin/Gemzar.
High-Volume Hospitals Offer Better Outcomes After Radical Cystectomy and Radical Prostatectomy (5/8/2006)
Among patients undergoing radical cystectomy (removal of bladder) or radical prostatectomy (removal of prostate), the probability of dying during hospitalization was lower at hospitals that performed a greater number of these specific procedures (high-volume hospitals). Hospital volume was not linked with in-hospital mortality after radical nephrectomy (removal of kidney). These results were published in the Journal of Clinical Oncology.
Bladder Cancer - RecurrentCystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (3/9/2010)
The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according to the results of a study presented at the 2010 Genitourinary Cancers Symposium in San Francisco.
Intravesical Taxotere® Effective in Recurrent Superficial Bladder Cancer (7/21/2006)
According to an article recently published in the Journal of Clinical Oncology, administration of the chemotherapy agent Taxotere® (docetaxel) directly into the bladder appears to be an effective treatment option for patients with early bladder cancer that has recurred following standard therapies.
Molecular Technique May Improve Detection of Bladder Cancer Recurrences (5/22/2006)
According to a review published in the journal Urology, a laboratory technique known as fluorescence in situ hybridization (FISH) may allow for earlier and more complete detection of bladder cancer recurrence.
Addition of NMP22® BladderChek® Improves Detection of Recurrent Bladder Cancer (1/18/2006)
According to a recent article published in the Journal of the American Medical Association, the addition of the NMP22® BladderChek® test to cystoscopy improves the detection of recurrent bladder cancer compared to cystoscopy alone.
Aggressive Surgical Treatment of Bladder Cancer Benefits Patients over the Age of 80 (9/9/2004)
Researchers from the University of Michigan have reported that aggressive surgical management of bladder cancer in patients over the age of 80 may improve survival.
|
|
